Oncopeptides detects melflufen in glioblastoma tissue in three patients
The INSULA window-of-opportunity study at Oslo University Hospital found drug concentrations in surgically removed tumor matching preclinical levels.
PR
By Priya Raman · Science Reporter
Oct 11 12:14 ETSource: Oncodaily
The wire
- 01Patients with recurrent glioblastoma received melflufen before surgery; the active compound was detected in tumor samples from all three evaluated patients, meeting the primary endpoint for that study component.
- 02The result is early human evidence that the company's peptide drug conjugate platform can cross the blood-brain barrier, a route Oncopeptides says blocks more than 90% of conventional systemic cancer drugs.
- 03The open-label study measures uptake, distribution and cytotoxic mechanism, not progression-free or overall survival, and recruitment continues toward about 10 patients.
From the source
Read at oncodaily.comOncopeptides Reports Blood-Brain Barrier Penetration in Glioblastoma INSULA Study
Oncopeptides announced that initial data from three patients in its ongoing INSULA study showed that its peptide drug conjugate platform crossed the human blood-brain barrier and reached glioblastoma tissue. The study examines a central challenge in brain cancer treatment: whether a systemically administered drug can reach the tumor.
